Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iSpecimen (ISPC) EBITDA (2020 - 2025)

iSpecimen has reported EBITDA over the past 6 years, most recently at -$5.0 million for Q4 2025.

  • Quarterly results put EBITDA at -$5.0 million for Q4 2025, up 17.29% from a year ago — trailing twelve months through Dec 2025 was -$10.5 million (up 16.09% YoY), and the annual figure for FY2025 was -$10.5 million, up 16.09%.
  • EBITDA for Q4 2025 was -$5.0 million at iSpecimen, down from -$2.8 million in the prior quarter.
  • Over the last five years, EBITDA for ISPC hit a ceiling of -$942644.0 in Q1 2021 and a floor of -$6.0 million in Q4 2024.
  • Median EBITDA over the past 5 years was -$2.3 million (2022), compared with a mean of -$2.5 million.
  • Biggest five-year swings in EBITDA: crashed 401.15% in 2021 and later soared 50.35% in 2025.
  • iSpecimen's EBITDA stood at -$2.0 million in 2021, then decreased by 7.35% to -$2.1 million in 2022, then plummeted by 34.06% to -$2.9 million in 2023, then plummeted by 110.62% to -$6.0 million in 2024, then grew by 17.29% to -$5.0 million in 2025.
  • The last three reported values for EBITDA were -$5.0 million (Q4 2025), -$2.8 million (Q3 2025), and -$1.0 million (Q2 2025) per Business Quant data.